AVS
Sean Gilligan started their work experience at Boston Scientific in 1994, where they held various positions over a period of 27 years. Sean served as the Vice President of Program Management, R&D, where they were a member of the Interventional Cardiology Global Leadership team and had expanded portfolio and project management responsibilities. Sean also had direct leadership of the Project Management team across multiple sites. Sean later became the Director of Program Management, R&D, where they established and led the local Project Management and R&D team and was responsible for executing product and technology development programs. Sean also led the Drug Eluting Stent program, LOTUS Edge™, and transferred the technology from a corporate research project to a full product development project. In 2023, Sean Gilligan joined Amplitude Vascular Systems as the Chief Operations Officer.
Sean Gilligan attended University College Dublin from 1986 to 1990, where they obtained a Bachelor of Science degree in Mechanical Engineering. Later, in 2001, they completed their education at Oxford Brookes University, earning a Master of Business Administration (MBA) degree with a focus on Business Administration and Management.
This person is not in any offices
AVS
AVS is an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease. It was founded in 2018 by Hitinder Gurm, M.D., Interventional Cardiologist and Chief Clinical Officer at University of Michigan, and Robert Chisena, Ph.D., Chief Technical Officer at AVS. They are redefining interventional therapy for severely calcified lesions with their Pulse IVL System, which uses a novel pulsatile mechanism of action to shatter calcium and expand narrowed vessels, all with a single device.